Current Research Studies
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS2)
What is the goal of the study?
This is a Phase 3, double-blind, randomized, vehicle-controlled study of ruxolitinib 1.5% cream in participants at least 12 years of age with a confirmed diagnosis of Hidradenitis Suppurativa. The study will consist of a 16-week Double-Blind Vehicle Controlled Period followed by a 36-week open label extension period.
Who can participate in the study?
Please contact the study team listed below to learn more.